ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
Dow Jones
38,239.66
0.40%
US Dollar vs MXN
17.1601
0.00%
Brent Oil
88.165
0.00%
Bitcoin
63,048.29
-1.08%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Incyte Corporation (INCY)

  7. Incyte Corporation (INCY) Noticias

INCY

Incyte (INCY)

Incyte Corporation
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:INCY
FechaHoraFuenteTítuloSímboloCompañía
23/04/202417:11Business WireIncyte annonce l'acquisition d'Escient Pharmaceuticals et de son portefeuille d'antagonistes MRGPR oraux premiers de leur catégorieNASDAQ:INCYIncyte Corporation
23/04/202417:01Business WireIncyte gibt Übernahme von Escient Pharmaceuticals und dessen Pipeline oraler First-in-Class-MRGPR-Antagonisten bekanntNASDAQ:INCYIncyte Corporation
23/04/202406:00Business WireIncyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR AntagonistsNASDAQ:INCYIncyte Corporation
11/04/202407:00Business WireIncyte to Report First Quarter Financial ResultsNASDAQ:INCYIncyte Corporation
01/04/202407:30Business WireIncyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast AsiaNASDAQ:INCYIncyte Corporation
29/03/202415:30Business WireIncyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:INCYIncyte Corporation
11/03/202407:57Business WireIncyte gibt neue Daten aus Phase-2-Studie zur Untersuchung von Ruxolitinib-Creme (Opzelura®) bei Patienten mit leichter bis mittelschwerer Hidradenitis Suppurativa bekanntNASDAQ:INCYIncyte Corporation
11/03/202407:57Business WireIncyte annonce de nouvelles données de l’étude de phase 2 évaluant le ruxolitinib crème (Opzelura®) chez les patients atteints d’hidradénite suppurée légère à modéréeNASDAQ:INCYIncyte Corporation
11/03/202405:06Business WireIncyte présente de nouvelles données de l’étude de phase 2 évaluant le povorcitinib chez des patients atteints de prurigo nodulaireNASDAQ:INCYIncyte Corporation
11/03/202404:53Business WireIncyte legt neue brandaktuelle Daten aus Phase-2-Studie zur Prüfung von Povorcitinib bei Patienten mit Prurigo nodularis vorNASDAQ:INCYIncyte Corporation
10/03/202415:05Business WireIncyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis SuppurativaNASDAQ:INCYIncyte Corporation
10/03/202415:05Business WireIncyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo NodularisNASDAQ:INCYIncyte Corporation
04/03/202413:38Business WireDe nouvelles données dérivées du portefeuille dermatologique croissant d’Incyte seront présentées lors de l’assemblée annuelle 2024 de l’American Academy of Dermatology (AAD)NASDAQ:INCYIncyte Corporation
04/03/202413:02Business WireNeue Daten aus dem wachsenden Dermatologieportfolio von Incyte werden bei Jahresversammlung 2024 der American Academy of Dermatology (AAD) präsentiertNASDAQ:INCYIncyte Corporation
04/03/202407:00Business WireNew Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual MeetingNASDAQ:INCYIncyte Corporation
29/02/202409:19Business WireIncyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AINASDAQ:INCYIncyte Corporation
29/02/202406:30GlobeNewswire Inc.Knight Therapeutics Announces Launch of Minjuvi® in BrazilNASDAQ:INCYIncyte Corporation
28/02/202408:11Business WireIncyte annonce que la Food and Drug Administration des États-Unis accorde une évaluation prioritaire à l’axatilimab pour le traitement de la maladie chronique du greffon contre l’hôteNASDAQ:INCYIncyte Corporation
28/02/202406:15Business WireIncyte gibt bekannt, dass die US-Arzneimittelbehörde FDA Axatilimab für die Behandlung der chronischen Graft-Versus- Host-Krankheit als vorrangig eingestuft hatNASDAQ:INCYIncyte Corporation
27/02/202415:08Business WireIncyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host DiseaseNASDAQ:INCYIncyte Corporation
16/02/202415:04Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:INCYIncyte Corporation
16/02/202411:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INCYIncyte Corporation
15/02/202407:00Business WireIncyte to Present at Upcoming Investor ConferenceNASDAQ:INCYIncyte Corporation
13/02/202416:06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:INCYIncyte Corporation
13/02/202415:03Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:INCYIncyte Corporation
13/02/202406:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:INCYIncyte Corporation
13/02/202406:00Business WireIncyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance and Highlights R&D PrioritiesNASDAQ:INCYIncyte Corporation
06/02/202403:08Business WireIncyte erhält exklusive weltweite Rechte für die Entwicklung und Vermarktung von Tafasitamab (Monjuvi ® )NASDAQ:INCYIncyte Corporation
05/02/202419:55Business WireIncyte obtient les droits exclusifs de développement et de commercialisation du tafasitamab (Monjuvi®) à l’échelle mondialeNASDAQ:INCYIncyte Corporation
05/02/202415:46Business WireIncyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)NASDAQ:INCYIncyte Corporation
 Showing the most relevant articles for your search:NASDAQ:INCY

Su Consulta Reciente

NASDAQ
TSLA
Tesla
USOTC
BNPQY
BNP Paribas (QX)
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
NKE
Nike
NASDAQ
AMZN
Amazon.com
AMEX
XLF
Financial Select Sector
NASDAQ
MSFT
Microsoft
NYSE
XOM
Exxon Mobil
NYSE
JPM
JP Morgan Chase
NYSE
KO
Coca Cola
NASDAQ
NVDA
NVIDIA
USOTC
ADDYY
Adidas (QX)
FX
EURMXN
Euro vs MXN
CCOM
US500
US 500
COIN
BTCUSD
Bitcoin
AMEX
XLE
Energy Select Sector SPDR
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados